105 related articles for article (PubMed ID: 29924510)
1. [Role of breast cancer resistance protein in drug disposition].
Wu XM; Sheng L; Jia YF; Li Y
Yao Xue Xue Bao; 2016 Sep; 51(9):1368-77. PubMed ID: 29924510
[TBL] [Abstract][Full Text] [Related]
2. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
4. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.
Mao Q; Unadkat JD
AAPS J; 2015 Jan; 17(1):65-82. PubMed ID: 25236865
[TBL] [Abstract][Full Text] [Related]
5. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
[TBL] [Abstract][Full Text] [Related]
6. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
7. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
8. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
9. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
10. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Shi P; Liao M; Chuang BC; Griffin R; Shi J; Hyer M; Fallon JK; Smith PC; Li C; Xia CQ
Xenobiotica; 2018 Nov; 48(11):1173-1183. PubMed ID: 29098941
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
[TBL] [Abstract][Full Text] [Related]
14. Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2.
Nishihashi K; Kawashima K; Nomura T; Urakami-Takebayashi Y; Miyazaki M; Takano M; Nagai J
Biol Pharm Bull; 2017; 40(1):82-87. PubMed ID: 28049953
[TBL] [Abstract][Full Text] [Related]
15. Marine natural products as breast cancer resistance protein inhibitors.
Cherigo L; Lopez D; Martinez-Luis S
Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646
[TBL] [Abstract][Full Text] [Related]
16. Interplay of metabolizing enzymes and transporter of xenobiotics.
Lim HY; Ho QS; Wong KP
Xenobiotica; 2016; 46(1):25-33. PubMed ID: 26226519
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line.
Caetano-Pinto P; Janssen MJ; Gijzen L; Verscheijden L; Wilmer MJ; Masereeuw R
Mol Pharm; 2016 Mar; 13(3):933-44. PubMed ID: 26871298
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2.
Harwood MD; Neuhoff S; Rostami-Hodjegan A; Warhurst G
J Pharm Sci; 2016 Apr; 105(4):1370-5. PubMed ID: 26952881
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.
Hodin S; Basset T; Jacqueroux E; Delezay O; Clotagatide A; Perek N; Mismetti P; Delavenne X
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):183-191. PubMed ID: 28895074
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer resistance protein (BCRP/ABCG2).
Staud F; Pavek P
Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
